Clinical trials: Schizoaffective Disorder, injection or injectable or infusion or IV or syringe or subcutaneous, open to volunteers
- Condition Schizoaffective Disorder
- Drug or intervention injection OR injectable OR infusion OR IV OR syringe OR subcutaneous
- Status Open to volunteers
Schizophrenia / Schizoaffective Disorder, SCHIZOPHRENIA 1 (Disorder)
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 3
In Study 3, all tasks and models from Aim 1 will be evaluated in a large community sample of online participants recruited through Prolific.
- Conditions
- Schizophrenia / Schizoaffective Disorder, SCHIZOPHRENIA 1 (Disorder), Healthy Adult
- Trial name
- CNTRACS (NCT07900893)
- Testing
- Motion Perception Task, Sine Wave Speech Task, Volatility Task
- Where
- 2 sites in United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia Disorder, Schizoaffective Disorder
Incentives and Long-Acting Injectable Adherence After Involuntary Hospitalization
This study is a randomized controlled trial evaluating the impact of financial incentives on medication adherence among individuals with schizophrenia, schizoaffective disorder, or bipolar disorder and/or co-occurring substance…
- Conditions
- Schizophrenia Disorder, Schizoaffective Disorder, Bipolar Disorder (BD), Substance Use Disorder (SUD)
- Trial name
- NCT07130500
- Testing
- Financial incentives for adherence to long-acting injectable medication, Standard of care with monthly surveys
- Where
- 6 sites in United States
- Volunteers
- 1,000 people
- Sponsor
- Stanford University
SCHIZOPHRENIA 1 (Disorder), Schizoaffective Disorder
Cognitive Neurocomputational Task Reliability & Clinical Applications Consortium (CNTRACS): Study 1
In Study 1, investigators will test the ability of each of the seven paradigms to differentiate between schizophrenia (SZ)/schizoaffective disorder (SZA) and matched healthy control subjects (HC) and to predict individual…
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Schizoaffective Disorder, Healthy Adult Participants
- Trial name
- CNTRACS (NCT07853807)
- Testing
- Motion Perception Task, Sine Wave Speech Task, Volatility Task
- Where
- 5 sites in United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder
Cognitive Neurocomputational Task Reliability and Clinical Applications Consortium: Study 2
In Study 2, investigators will recruit individuals with schizophrenia (SZ) and or schizoaffective disorder (SZA) and healthy controls (HC) using optimized behavioral tasks to replicate the behavioral findings from Study 1 and to…
- Conditions
- SCHIZOPHRENIA 1 (Disorder), Schizo Affective Disorder, Healthy Adult
- Trial name
- CNTRACS 2 (NCT07875790)
- Testing
- Motion Perception Task, Sine Wave Speech Task, Volatility Task
- Where
- 5 sites in United States
- Volunteers
- 325 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Schizophrenia, Schizo Affective Disorder
Clinical Trial of an IL-23 Inhibitor for Immune Activation in Clinical Trial of an IL-23 Inhibitor for Immune Activation in People With Schizophrenia
This 16 week clinical trial investigates a precision-medicine approach to schizophrenia by targeting a biologically distinct subgroup,-approximately one-third of patients-characterized by the presence of anti-gliadin antibodies…
- Conditions
- Schizophrenia, Schizo Affective Disorder, Healthy
- Trial name
- NCT07615075
- Testing
- IL-23
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior
Rituximab Treatment for Psychosis And/or Obsessive Compulsive Disorder with Probable Immune System Involvement
The primary objective for this study is to evaluate whether Rituximab as compared to placebo is a clinically effective treatment for a subgroup of patients suffering from psychosis and/or obsessive-compulsive disorder (OCD) or…
- Conditions
- Obsessive-Compulsive Disorder, Obsessive-Compulsive Behavior, Schizophrenia, Delusional Disorder
- Trial name
- Ra-P-OCD (NCT04323566)
- Testing
- Rituximab
- Where
- Sweden
- Volunteers
- 40 people
- Sponsor
- Uppsala University Hospital
Schizo-Affective Type of Psychosis, Schizophrenia
Ocrelizumab for Psychosis by Autoimmunity
Some people who have what doctors currently call schizophrenia or bipolar disease may actually have a brain disease caused by auto-antibodies.
- Trial name
- OPA (NCT03971487)
- Testing
- Psychosis and cognitive assessments, Physical and neuro-cognitive evaluations, Safety labs and electrocardiogram
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- The Methodist Hospital Research Institute
Healthy Adult Participants
Pharmacokinetics and Relative Bioavailability of Intranasal vs Intramuscular Olanzapine in Healthy Adult Participants
This is a Phase 1, open-label, 5-period, 2-sequence, single ascending dose study designed to assess the pharmacokinetics, dose proportionality, safety, and tolerability of NRL-1004 (olanzapine nasal spray), and to assess the…
- Trial name
- NCT07921966
- Testing
- NRL-1004 2.5 mg, ZYPREXA IM 10mg, NRL-1004 5.0 mg
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Neurelis, Inc.